| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.03 | 0.3 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.3 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | -0.035 | 0.3 |